PT-141
PT-141 (Bremelanotide) is used to treat sexual dysfunction in both men and women. It works directly on the nervous system rather than the vascular system.
Common Dosage
1mg - 2mg as needed
Category
Sexual Health
- Increased libido
- Treatment of ED
- Enhanced arousal
PT-141, chemically known as Bremelanotide, was originally synthesized as a derivative of Melanotan II during melanocortin receptor research at the University of Arizona. Researchers discovered that in addition to tanning effects, Melanotan II caused spontaneous erections in male subjects — a surprising finding that redirected research toward sexual dysfunction. PT-141 was developed as a purified version targeting sexual function specifically, and was eventually approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 works through the melanocortin system — specifically MC3R and MC4R receptors in the brain — to enhance sexual arousal and desire at the central nervous system level. This is fundamentally different from PDE5 inhibitors (Viagra, Cialis) which work peripherally on vascular smooth muscle. PT-141's central action means it addresses desire and arousal, not just mechanical erectile function. It does not require sexual stimulation to work, though stimulation enhances its effects.
- Hypoactive sexual desire disorder (HSDD) in women — FDA-approved indication
- Erectile dysfunction in men, including cases unresponsive to PDE5 inhibitors
- Female sexual arousal disorder
- Psychological and stress-related sexual dysfunction
- Post-menopausal sexual dysfunction research
FDA RECONNECT Trials
The Phase III RECONNECT trials demonstrated that Bremelanotide (Vyleesi) significantly improved desire scores and distress related to low desire in premenopausal women with HSDD. The effect was clinically meaningful compared to placebo, with onset typically within 45 minutes.
PDE5 Inhibitor Non-Responders
Male subjects with ED who had failed adequate trials of sildenafil or tadalafil have shown response to PT-141, consistent with the different (central vs. peripheral) mechanism of action. This positions PT-141 as a complementary or alternative approach rather than a competitor to traditional ED medications.
Psychological ED
PT-141 has shown particular promise in men whose ED has a strong psychological component — performance anxiety, relationship stress, or depression-related. The central mechanism appears well-suited to addressing desire and arousal deficits that are primarily neurological rather than vascular.
- Nausea and flushing are the most common side effects — occurring in approximately 40% of users, typically manageable
- Blood pressure changes — transient hypotension followed by hypertension in some cases; caution advised with antihypertensives
- Facial flushing and hyperpigmentation with frequent use due to melanocortin stimulation
- Not intended for daily use — recommended dosing is on-demand, maximum 8mg per week
- Contraindicated with high cardiovascular risk; the transient BP changes carry risk in susceptible individuals
- Nausea
- Flushing
- Headache